Artiva Biotherapeutics
Develops cryopreserved allogeneic NK-cell candidates for autoimmune diseases and cancer.
$11.14
After-hours close+0.06 (+0.54%)
At close$11.08(−7.20%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.54 | — | — |
| Aug 2026 | −$0.63 | −$0.63 | −0.8% |
| Aug 2026 | −$0.64 | −$0.63 | +1.6% |
| May 2026 | −$0.88 | −$0.95 | −8.0% |
| Mar 2026 | −$0.87 | −$0.84 | +3.4% |
The latest year is open to everyone — the 11 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| Jun 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.54 | — | — | — | — | — |
| Aug 6, 2026 | −$0.63 | −$0.63 | −0.8% | — | — | — |
| Aug 5, 2026 | −$0.64 | −$0.63 | +1.6% | — | — | — |
| May 8, 2026 | −$0.88 | −$0.95 | −8.0% | — | — | — |
| Mar 10, 2026 | −$0.87 | −$0.84 | +3.4% | — | — | — |
The latest year is open to everyone — the 11 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 6, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 25, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 29, 2024 | ||||||
| Jun 30, 2024 | ||||||
| Dec 31, 2023 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||